NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

未分化淋巴瘤激酶(ALK)抑制劑的全球市場:2021年∼2025年

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2021-2025

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 1007845
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
未分化淋巴瘤激酶(ALK)抑制劑的全球市場:2021年∼2025年 Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2021-2025
出版日期: 2021年04月23日內容資訊: 英文 120 Pages
簡介

世界的未分化淋巴瘤激酶(ALK)抑制劑的市場規模在2021年∼2025年間,預測將成長到34億3000萬美元,在預測期間中預計將以22%的年複合成長率增長。

該市場成長的主要因素有未分化淋巴瘤激酶抑製劑的高目標親和力和特異性、高肺癌患病率以及患者宣傳計劃。

本報告涵括未分化淋巴瘤激酶(ALK)抑制劑的全球市場的整體分析,提供市場規模與預測,趨勢,成長要素,課題,及約25供應商的分析。

目錄

  • 摘要整理
    • 市場概要
  • 市場形勢
    • 市場生態系統
    • 價值鏈分析
  • 市場粒度分級
    • 市場定義
    • 市場區隔分析
    • 2020年的市場規模
    • 市場預測:2020年∼2025年預測
  • 波特的五力分析
    • 五力分析
    • 買主談判力
    • 供應商談判力
    • 新加入廠商的威脅
    • 替代品的威脅
    • 對手的威脅
    • 市場情況

    市場區隔:各類型

    • 市場區隔
    • 各類型比較
    • 第2代 ALK 抑制劑:市場規模與預測(2020年∼2025年)
    • 第1代 ALK 抑制劑:市場規模與預測(2020年∼2025年)
    • 第3代 ALK 抑制劑:市場規模與預測(2020年∼2025年)
    • 各類型的市場機會
  • 客戶形勢
  • 各地區形勢
    • 各地區市場區隔
    • 各地區比較
    • 北美:市場規模與預測(2020年∼2025年)
    • 歐洲:市場規模與預測(2020年∼2025年)
    • 亞洲:市場規模與預測(2020年∼2025年)
    • 其他地區:市場規模與預測(2020年∼2025年)
    • 主要國家
    • 各地區的市場機會
    • 市場推動因素
    • 市場課題
    • 市場趨勢
  • 業者情勢
    • 概要
    • 業者情勢
    • 創造性破壞狀況
  • 供應商分析
    • 交易廠商
    • 供應商的市場定位
    • Betta Pharmaceuticals Co. Ltd.
    • Bio-Techne Corp.
    • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Helsinn Healthcare SA
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Co. Ltd.
    • Turning Point Therapeutics Inc.
  • 附錄
    • 調查範圍
    • 美金的貨幣換算比率
    • 調查手法
    • 簡稱一覽
目錄
Product Code: IRTNTR43929

Technavio has been monitoring the anaplastic lymphoma kinase (ALK) inhibitors market and it is poised to grow by $ 3.43 billion during 2021-2025, progressing at a CAGR of almost 22% during the forecast period. Our report on anaplastic lymphoma kinase (ALK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of ALK inhibitors, high prevalence of lung cancer, and presence of patient assistance programs. In addition, the high target affinity and specificity of ALK inhibitors is anticipated to boost the growth of the market as well.

The anaplastic lymphoma kinase (ALK) inhibitors market analysis includes type segment and geographic landscape.

Technavio's anaplastic lymphoma kinase (ALK) inhibitors market is segmented as below:

By Type

  • Second-generation ALK inhibitors
  • First-generation ALK inhibitors
  • Third-generation ALK inhibitors

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the expansion of research areas and combination therapies as one of the prime reasons driving the anaplastic lymphoma kinase (ALK) inhibitors market growth during the next few years. Also, strategic alliances and growing awareness about lung cancer will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on anaplastic lymphoma kinase (ALK) inhibitors market covers the following areas:

  • Anaplastic lymphoma kinase (ALK) inhibitors market sizing
  • Anaplastic lymphoma kinase (ALK) inhibitors market forecast
  • Anaplastic lymphoma kinase (ALK) inhibitors market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anaplastic lymphoma kinase (ALK) inhibitors market vendors that include Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc. Also, the anaplastic lymphoma kinase (ALK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Type
    • Market segments
    • Comparison by Type
    • Second-generation ALK inhibitors - Market size and forecast 2020-2025
    • First-generation ALK inhibitors - Market size and forecast 2020-2025
    • Third-generation ALK inhibitors - Market size and forecast 2020-2025
    • Market opportunity by Type
  • Customer Landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Overview
    • Vendor landscape
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Betta Pharmaceuticals Co. Ltd.
    • Bio-Techne Corp.
    • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Helsinn Healthcare SA
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Co. Ltd.
    • Turning Point Therapeutics Inc.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Type - Market share 2020-2025 (%)
  • 22: Comparison by Type
  • 23: Second-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
  • 24: Second-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
  • 25: First-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
  • 26: First-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
  • 27: Third-generation ALK inhibitors - Market size and forecast 2020-2025 ($ million)
  • 28: Third-generation ALK inhibitors - Year-over-year growth 2020-2025 (%)
  • 29: Market opportunity by Type
  • 30: Customer landscape
  • 31: Market share by geography 2020-2025 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2020-2025 ($ million)
  • 34: North America - Year-over-year growth 2020-2025 (%)
  • 35: Europe - Market size and forecast 2020-2025 ($ million)
  • 36: Europe - Year-over-year growth 2020-2025 (%)
  • 37: Asia - Market size and forecast 2020-2025 ($ million)
  • 38: Asia - Year-over-year growth 2020-2025 (%)
  • 39: ROW - Market size and forecast 2020-2025 ($ million)
  • 40: ROW - Year-over-year growth 2020-2025 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Betta Pharmaceuticals Co. Ltd. - Overview
  • 50: Betta Pharmaceuticals Co. Ltd. - Product and service
  • 51: Betta Pharmaceuticals Co. Ltd. - Key offerings
  • 52: Betta Pharmaceuticals Co. Ltd. - Key customers
  • 53: Betta Pharmaceuticals Co. Ltd. - Segment focus
  • 54: Bio-Techne Corp. - Overview
  • 55: Bio-Techne Corp. - Business segments
  • 56: Bio-Techne Corp. - Key offerings
  • 57: Bio-Techne Corp. - Key customers
  • 58: Bio-Techne Corp. - Segment focus
  • 59: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Overview
  • 60: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Product and service
  • 61: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Key offerings
  • 62: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Key customers
  • 63: Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Segment focus
  • 64: F. Hoffmann-La Roche Ltd. - Overview
  • 65: F. Hoffmann-La Roche Ltd. - Business segments
  • 66: F. Hoffmann-La Roche Ltd. - Key offerings
  • 67: F. Hoffmann-La Roche Ltd. - Key customers
  • 68: F. Hoffmann-La Roche Ltd. - Segment focus
  • 69: Helsinn Healthcare SA - Overview
  • 70: Helsinn Healthcare SA - Product and service
  • 71: Helsinn Healthcare SA - Key offerings
  • 72: Helsinn Healthcare SA - Key customers
  • 73: Helsinn Healthcare SA - Segment focus
  • 74: Merck KGaA - Overview
  • 75: Merck KGaA - Business segments
  • 76: Merck KGaA - Key offerings
  • 77: Merck KGaA - Key customers
  • 78: Merck KGaA - Segment focus
  • 79: Novartis AG - Overview
  • 80: Novartis AG - Business segments
  • 81: Novartis AG - Key offerings
  • 82: Novartis AG - Key customers
  • 83: Novartis AG - Segment focus
  • 84: Pfizer Inc. - Overview
  • 85: Pfizer Inc. - Business segments
  • 86: Pfizer Inc. - Key offerings
  • 87: Pfizer Inc. - Key customers
  • 88: Pfizer Inc. - Segment focus
  • 89: Takeda Pharmaceutical Co. Ltd. - Overview
  • 90: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 91: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 92: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 93: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 94: Turning Point Therapeutics Inc. - Overview
  • 95: Turning Point Therapeutics Inc. - Product and service
  • 96: Turning Point Therapeutics Inc. - Key offerings
  • 97: Turning Point Therapeutics Inc. - Key customers
  • 98: Turning Point Therapeutics Inc. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations